A Phase 3 interventional study of Eloralintide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Recruiting at 158 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing eloralintide in Obesity — 14 open to participants now, 15 under way, 8 of them phase 3. eloralintide · Obesity.
Among the 22 studies testing eloralintide in Obesity, this one is the 3rd largest by planned enrollment, is one of 12 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 8 of the 14 other live ones, and was the 11th registered.
11,536 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →14 of the 22 studies testing eloralintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Brazil, China and 7 more countries
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–60 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Singapore
Ages 18–65 · Healthy volunteers
Eli Lilly and Company · Sites in Germany, Sweden
Ages 18–70 · Healthy volunteers
Eli Lilly and Company · Sites in United States
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2022; this study’s year is marked. 12 started in 2026.
This study's planned enrollment of 1,980 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 315 across the 22 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 1 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 536 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
117 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 60 finished, 28 (47%) have results posted.
Among the 117 studies in Obesity by Eli Lilly and Company, this one is the 9th largest by planned enrollment of the 116 interventional ones that give a count, is one of 25 that started in 2026, is one of 51 in phase 3, reaches primary completion later than 36 of the 54 other live ones, and was the 93rd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
7 of the studies testing eloralintide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07738614Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight | 2026-12 |
| NCT07215559Eli Lilly and CompanyA Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes | 2027-03 |
| NCT07808060Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight | 2027-06 |
| NCT07765511Eli Lilly and CompanyA Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes | 2027-06 |
| NCT07665879Eli Lilly and CompanyA Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity | 2027-08 |
Add all 7 to your calendar (.ics) → With an account.
Among the 22 studies testing eloralintide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 117 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have (BMI) at screening of the following:
27 kg/m2 with at least one of the following weight-related health conditions at screening:
Exclusion Criteria:
Have had within 90 days prior to screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive eloralintide subcutaneously (SC)
Drug: Eloralintide
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive eloralintide SC
Drug: Eloralintide
Participants will receive placebo SC
Drug: Placebo
Administered SC
Also known as: LY3841136
Administered SC
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 64
Percent Change from Baseline in Total Body Fat Mass
Time frame: Baseline, Week 64
Change from Baseline in Waist Circumference
Time frame: Baseline, Week 64
Percent Change from Baseline in Triglycerides
Time frame: Baseline, Week 64
Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 64
Time to Onset of Type 2 Diabetes (T2D)
Time to Onset of Type 2 Diabetes (T2D) in Participants with Prediabetes at Randomization
Time frame: Baseline to Week 168 and Week 191
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 64
Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 64
Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 64
Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)
Time frame: Baseline, Week 64
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)
Time frame: Baseline, Week 64
Change from Baseline in Short Form-36 Version 2 (SF-36 v2) Score
Time frame: Baseline, Week 64
Change from Baseline in EQ-5D-5L
Time frame: Baseline, Week 64
Change from Baseline in Control of Eating Questionnaire (CoEQ) Score
Time frame: Baseline, Week 64
Achievement of Improved Categorical Shift in Patient Global Improvement of Status (PGIS) Physical Function Weight
Time frame: Baseline, Week 64
Change in Medication Use
Time frame: Baseline through Week 64
Percent Change from Baseline in Body Weight in Participants with Prediabetes at Randomization
Time frame: Baseline, Week 168
Pharmacokinetics (PK): Maximum Concentration at Steady State (Cmax,ss)
Time frame: Baseline through Week 64
PK: Area Under the Concentration Versus Time Curve for One Dosing Interval at Steady State (AUC(0-ᴛ)ss)
Time frame: Baseline through Week 64
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Showing the first 100 of 158 sites across 15 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Mar 2028, 25 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 25 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to trackQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eloralintide